Dianomi Therapeutics has licensed a second suite of intellectual property (IP) from the Wisconsin Alumni Research Foundation (WARF) to expand the use of its Mineral Coated Microparticle (MCM) technology into…

Dianomi Therapeutics, a biohealth company focused on osteoarthritis and pain with technology, has received a $3 million investment from its new partner, Ligand Pharmaceuticals, the company announced recently. According to a…